Screener
Palvella Therapeutics PVLA Accrued Liabilities And Other Liabilities Current
Accrued Liabilities And Other Liabilities Current at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept pvla:AccruedLiabilitiesAndOtherLiabilitiesCurrent.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $5,443 | $4,595 |
| Derivative liabilities – contingent value right liability | — | 2,196 |
| Current portion of operating lease liability | 209 | 202 |
| Accrued expenses and other current liabilities | 3,463 | 4,351 |
| Total current liabilities | 9,115 | 11,344 |
| Long-term portion of operating lease liability | 375 | 431 |
| Royalty agreement liability | 19,799 | 17,760 |
| Derivative liabilities – royalty agreement | 2,157 | 2,041 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's accrued liabilities and other liabilities current?
- Palvella Therapeutics (PVLA) reported accrued liabilities and other liabilities current of $3.46M in Q1 2026.
- How has Palvella Therapeutics's accrued liabilities and other liabilities current changed year-over-year?
- Palvella Therapeutics's accrued liabilities and other liabilities current increased by 35.1% year-over-year, from $2.56M to $3.46M.
- What is the long-term trend for Palvella Therapeutics's accrued liabilities and other liabilities current?
- Over 2 years (2023 to 2025), Palvella Therapeutics's accrued liabilities and other liabilities current has grown at a 74.8% compound annual growth rate (CAGR), from $1.42M to $4.35M.
- What does accrued liabilities and other liabilities current mean?
- This balance captures short-term obligations for goods or services received but not yet invoiced or paid, including accrued payroll, professional fees, and clinical trial expenses. It reflects the company's immediate operational commitments and short-term working capital requirements. Monitoring this figure provides insight into the company's near-term cash outflow obligations and operational scale.
Ask your AI about Palvella Therapeutics's accrued liabilities and other liabilities current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude